Segaloff 1985.

Study characteristics
Methods	Accrual dates: July 1971 to October 1976 Sample size: 427 Number of centres: 11(USA) Randomisation method: 'randomised from a central statistical office' Baseline comparability: no significant imbalance apparent or reported
Participants	Female Age range: > 40 to 65+ years 91% MBC, 9% locally advanced Unclear if a first line trial for MBC 'patients eligible if they had a trial with 1 or 2 single agents'
Interventions	CMFP vs CMFVP Arm I: (CMFP) Cyclophosphamide + methotrexate + 5‐fluorouracil + prednisone Arm II: (CMFVP) arm I + vincristine
Outcomes	Overall survival Response Toxicity
Notes	All randomised patients included in analyses. Mean follow‐up times reported, 17 months CMFP arm and 19 months CMFVP arm. Survival curve calculated using life table methodology. Time‐to‐event data estimated from statistics presented in trial publication. Toxic related deaths not reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	B ‐ Unclear
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear, patients less than 1 year postmenopausal were centrally randomised
Blinding (performance bias and detection bias) All outcomes	Unclear risk	B ‐ Unclear
Incomplete outcome data (attrition bias) Response	Unclear risk	B ‐ Unclear
Incomplete outcome data (attrition bias) Toxicity	Unclear risk	B ‐ Unclear
Incomplete outcome data (attrition bias) Overall survival	Unclear risk	B ‐ Unclear
Selective reporting (reporting bias)	Low risk	A ‐ Adequate, outcomes reported
Other bias	Low risk	A ‐ Adequate